HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection-Reference-Cited by-同舟云学术

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

Published:2011-03 Issue:11 Volume:29 Page:2011-2014
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Kemp Troy J.,Hildesheim Allan,Safaeian Mahboobeh,Dauner Joseph G.,Pan Yuanji,Porras Carolina,Schiller John T.,Lowy Douglas R.,Herrero Rolando,Pinto Ligia A.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference13 articles.

1. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women;Paavonen;Lancet,2009

2. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up;Villa;Br J Cancer,2006

3. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years;Brown;J Infect Dis,2009

4. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection;Breitburd;J Virol,1995

5. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas;Suzich;Proc Natl Acad Sci U S A,1995

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empowering standardization of cancer vaccines through ontology: enhanced modeling and data analysis;Journal of Biomedical Semantics;2024-06-19

2. Vulvar intraepithelial neoplasia associated with HPV infection: clinical, diagnostic, therapeutic and prophylactic aspects: A review;Gynecology;2023-10-04

3. Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model;Vaccine;2023-07

4. Human Papillomavirus Vaccines;Plotkin's Vaccines;2023

5. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings;BMC Women's Health;2022-06-16